SA522433319B1 - FimH طافرة ، تركيبات بها واستخدامته - Google Patents

FimH طافرة ، تركيبات بها واستخدامته

Info

Publication number
SA522433319B1
SA522433319B1 SA522433319A SA522433319A SA522433319B1 SA 522433319 B1 SA522433319 B1 SA 522433319B1 SA 522433319 A SA522433319 A SA 522433319A SA 522433319 A SA522433319 A SA 522433319A SA 522433319 B1 SA522433319 B1 SA 522433319B1
Authority
SA
Saudi Arabia
Prior art keywords
fimh
formulations
polypeptides
lectin domain
mutant
Prior art date
Application number
SA522433319A
Other languages
Arabic (ar)
English (en)
Inventor
جان جريجبسترا،
ايفيلين، مارلين ويردينبورج،
لوريس، جاكوب فيتسما،
جيرون جورتسين،
كيلين، كريستينا فاي،
Original Assignee
جانسين فارماسوتيكا ، انك.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by جانسين فارماسوتيكا ، انك. filed Critical جانسين فارماسوتيكا ، انك.
Publication of SA522433319B1 publication Critical patent/SA522433319B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SA522433319A 2020-01-16 2022-07-16 FimH طافرة ، تركيبات بها واستخدامته SA522433319B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20152217 2020-01-16
PCT/EP2021/050707 WO2021144369A1 (en) 2020-01-16 2021-01-14 Fimh mutant, compositions therewith and use thereof

Publications (1)

Publication Number Publication Date
SA522433319B1 true SA522433319B1 (ar) 2024-07-10

Family

ID=69174406

Family Applications (1)

Application Number Title Priority Date Filing Date
SA522433319A SA522433319B1 (ar) 2020-01-16 2022-07-16 FimH طافرة ، تركيبات بها واستخدامته

Country Status (25)

Country Link
US (3) US11421003B2 (https=)
EP (2) EP4090363B1 (https=)
JP (2) JP7485771B2 (https=)
KR (1) KR20220128372A (https=)
CN (1) CN115038461A (https=)
AR (1) AR121066A1 (https=)
AU (1) AU2021208493B2 (https=)
BR (1) BR112022013720A2 (https=)
CA (1) CA3168108A1 (https=)
DK (1) DK4090363T3 (https=)
ES (1) ES2987890T3 (https=)
FI (1) FI4090363T3 (https=)
HR (1) HRP20241370T1 (https=)
HU (1) HUE068985T2 (https=)
IL (1) IL294445B2 (https=)
LT (1) LT4090363T (https=)
MX (1) MX2022008830A (https=)
MY (1) MY209568A (https=)
PL (1) PL4090363T3 (https=)
PT (1) PT4090363T (https=)
RS (1) RS66031B1 (https=)
SA (1) SA522433319B1 (https=)
SI (1) SI4090363T1 (https=)
TW (2) TWI868297B (https=)
WO (1) WO2021144369A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
NZ790372A (en) 2020-02-23 2026-01-30 Pfizer Escherichia coli compositions and methods thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) * 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
US11725028B2 (en) * 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof
PE20241621A1 (es) * 2021-12-17 2024-08-07 Pfizer Composiciones de polinucleotidos y sus usos
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
JP7656656B2 (ja) * 2022-06-20 2025-04-03 ファイザー・インク 大腸菌ＦｉｍＨ変異体およびその使用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドａ単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
NZ338101A (en) 1997-04-01 2002-03-28 Corixa Corp Adjuvant compositions of Monophosphoryl Lipid A (MPL) and a phospholipid based surfactant (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)) suitable for intranasal administration
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
DE69935606T9 (de) 1998-10-16 2021-03-11 Glaxosmithkline Biologicals S.A. Adjuvanzsysteme und impfstoffe
US6759241B1 (en) 1999-10-04 2004-07-06 University Of Maryland Biotechnology Institute Adjuvant comprising a lipopolysaccharide antagonist
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
EP1299544A2 (en) 2000-07-07 2003-04-09 Medimmune, Inc. Fimh adhesin proteins and methods of use
EP1313502A4 (en) 2000-08-18 2005-10-19 Medimmune Inc ADMINISTRATIVE PROCEDURE OF FIMH PROTEIN AS A VACCINE AGAINST HARNWAY INFECTIONS
US20030199071A1 (en) 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
EP1874342B1 (en) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
CA2607595C (en) 2005-05-11 2018-11-27 Eth Zuerich Recombinant n-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
HRP20181259T1 (hr) 2008-02-20 2018-10-05 Glaxosmithkline Biologicals S.A. Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
CN102481312B (zh) 2009-06-05 2015-07-15 传染性疾病研究院 合成的吡喃葡萄糖脂佐剂
PL2811981T3 (pl) 2012-02-07 2019-09-30 Infectious Disease Research Institute Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania
RS59500B1 (sr) 2013-05-18 2019-12-31 Aduro Biotech Inc Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) * 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
CN106535927B (zh) 2014-02-24 2019-09-20 葛兰素史密丝克莱恩生物有限公司 新颖多糖及其用途
EP3294761A4 (en) * 2015-05-13 2019-04-03 University of Washington COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI
ES2839880T3 (es) 2015-07-07 2021-07-06 Janssen Vaccines & Prevention Bv Vacuna contra el VRS
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
LT4090363T (lt) 2020-01-16 2024-09-25 Janssen Pharmaceuticals, Inc. Fimh mutantas, kompozicijos su juo ir jų panaudojimas
US11725028B2 (en) 2021-01-12 2023-08-15 Janssen Pharmaceuticals, Inc. FimH mutants, compositions therewith and use thereof

Also Published As

Publication number Publication date
EP4090363A1 (en) 2022-11-23
BR112022013720A2 (pt) 2022-10-11
US11421003B2 (en) 2022-08-23
US20240294582A1 (en) 2024-09-05
HUE068985T2 (hu) 2025-02-28
RS66031B1 (sr) 2024-11-29
JP2024045126A (ja) 2024-04-02
IL294445A (en) 2022-09-01
JP2023500749A (ja) 2023-01-10
EP4461744A2 (en) 2024-11-13
JP7485771B2 (ja) 2024-05-16
DK4090363T3 (da) 2024-09-30
MY209568A (en) 2025-07-22
IL294445B1 (en) 2023-06-01
EP4090363B1 (en) 2024-09-04
SI4090363T1 (sl) 2024-10-30
WO2021144369A1 (en) 2021-07-22
US20210221856A1 (en) 2021-07-22
US12428449B2 (en) 2025-09-30
FI4090363T3 (fi) 2024-09-25
TW202537972A (zh) 2025-10-01
PL4090363T3 (pl) 2024-11-25
HRP20241370T1 (hr) 2024-12-20
TWI868297B (zh) 2025-01-01
CN115038461A (zh) 2022-09-09
US12012435B2 (en) 2024-06-18
US20230049056A1 (en) 2023-02-16
EP4461744A3 (en) 2025-01-08
PT4090363T (pt) 2024-09-19
AU2021208493A1 (en) 2022-06-30
KR20220128372A (ko) 2022-09-20
IL294445B2 (en) 2023-10-01
TW202140521A (zh) 2021-11-01
AU2021208493B2 (en) 2023-03-30
MX2022008830A (es) 2022-10-07
ES2987890T3 (es) 2024-11-18
LT4090363T (lt) 2024-09-25
CA3168108A1 (en) 2021-07-22
AR121066A1 (es) 2022-04-13

Similar Documents

Publication Publication Date Title
SA522433319B1 (ar) FimH طافرة ، تركيبات بها واستخدامته
PH12020551261A1 (en) Il-15 conjugates and uses thereof
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
HRP20220717T1 (hr) Modificirani pripravci mrna
MX2022000369A (es) Cepa bacteriana de bifidobacterium bifidum, las composiciones de la misma y usos relacionados.
HRP20231437T1 (hr) Il-15 i il-15ralpha sushi domena na temelju modulokina
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
MA40794A1 (fr) Nouveaux peptides et combinaisons de peptides et d'échafaudages destinés à être utilisés en immunothérapie contre le carcinome hépatocellulaire (chc) et d'autres cancers
BR112017025728A2 (pt) fragmentos mutantes da proteína ras
BR112022020438A2 (pt) Composições compreendendo três proteínas de fusão ospa para uso médico
SA522431304B1 (ar) عمليات تحضير اللاسميديتان وملح الأسيتات منه
MY205028A (en) Protein for treatment of inflammatory diseases
MX2021015154A (es) Composicion farmaceutica parenteral de agonista dual de glp1/2.
AR124604A1 (es) Mutantes de fimh, composiciones con los mismos y uso de los mismos
MY183392A (en) Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
MX2020008125A (es) Composiciones que comprenden berberina.
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
Imatani et al. Histatin 5 inhibits inflammatory cytokine induction from human gingival fibroblasts by Porphyromonas gingivalis
FR3063645B1 (fr) Acefapc pour le traitement des maladies acetylcholine dependantes
ZA202209632B (en) Molecules targeting mutant ras protein
Munblit et al. Modulating breast milk composition-the key to allergy prevention?
ZA202401042B (en) Protein compositions for the treatment of inflammatory diseases
WO2018200814A3 (en) Modified cyclic peptides and therapeutic use thereof
ITRM20040103A1 (it) Proteine di fusione comprendenti allergeni della famiglia delle ns-ltps, loro usi e composizioni farmaceutiche che le comprendono.